Related Experiment Video
Updated: May 17, 2026
08:01
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know
Jeffrey I Weitz1, David Gailani2
1Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Clinics in Laboratory Medicine
|May 15, 2026
Summary
New anticoagulants targeting factor XIa (FXIa) show promise for safer thrombosis treatment. These FXIa inhibitors may reduce clotting risks without increasing bleeding, advancing anticoagulation therapy.
Area of Science:
- Hematology
- Pharmacology
Background:
- Factor XI (FXI) and its activated form, factor XIa (FXIa), play a crucial role in thrombosis.
- Current anticoagulants carry risks of bleeding complications.
- There is a need for anticoagulants with improved safety profiles.
Purpose of the Study:
- To review unmet needs in anticoagulation.
- To explain the role of FXI in hemostasis and thrombosis.
- To provide insights into FXI/FXIa inhibitors and ongoing clinical trials.
Main Methods:
- Review of existing literature on FXI/FXIa.
- Analysis of FXI's role in coagulation pathways.
- Examination of FXI/FXIa inhibitors' effects on coagulation tests.
- Overview of current phase 3 clinical trials.
Main Results:
- FXIa inhibitors represent a novel class of anticoagulants.
- These inhibitors have the potential to reduce thrombosis without a dose-dependent increase in bleeding.
- FXI/FXIa inhibitors impact standard coagulation tests.
Conclusions:
- FXIa inhibitors offer a promising, safer alternative to traditional anticoagulants.
- Understanding FXI/FXIa is crucial for laboratory hematologists.
- Ongoing clinical trials will determine the clinical utility of these agents.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...